Bausch & Lomb Incorporated

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

DelveInsight's report on the Acute Ocular Pain Market forecasts significant growth (2020-2034) in the US, EU4, UK, and Japan. Key companies include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma, Ocular Therapeutix, Kala Pharmaceuticals, and Bausch & Lomb. Recent FDA approvals and ongoing research are driving market dynamics, with treatments like DEXTENZA, INVELTYS, and LOTEMAX SM addressing post-operative pain. The market is expected to surge due to increasing prevalence and pipeline product launches.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.

MIEBO is an ophthalmic solution for dry eye disease, administered 4 times daily. It was approved based on two clinical trials involving 1,217 patients. The trials showed MIEBO improved corneal surface and dryness symptom scores. Efficacy and side effects were consistent across sex, race, and age groups. Common side effects included blurred vision and headache.